Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 50

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 50
---
 be overcome (see “Strategy”).

<div align='center'>1</div>

Treatment and Prevention of Tick-Borne Disease (Babesiosis) We are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseloads, as further described below:

| ● | Treatment                                                                                                                                      
 of Chronic Tick-Borne Disease (Babesiosis). Babesia parasites are co-transmitted by the same ticks that transmit Borrelia,                     
 the Lyme disease bacterium. Although Lyme in the acute phase is generally viewed by the medical community as being treatable with antibiotics, 
 individuals who are not treated, or fail treatment, may go on to develop long term, and potentially debilitating, chronic symptoms such        
 as fatigue, body aches, and cognitive problems.1 This condition is defined by the Centers for Disease Control and Prevention                   
 (“CDC”) as Post-Treatment Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient community.2                                         
 Although there are no published estimates, key opinion leaders have stated that as many as 50% of Lyme/PTLDS patients are believed to          
 be co-infected with Babesia parasites, a diagnosis referred to in the Lyme community as “Chronic Babesiosis.” Prescribers                      
 in the Lyme disease community utilize a number of therapeutic modalities to manage the symptoms of Chronic Babesiosis, including FDA-approved  
 pharmaceuticals such as atovaquone and azithromycin (these are assumed to suppress the growth of Babesia parasites).3                          
 Recent                                                                                                                                         
 market data shows that Tafenoquine appears to be increasingly prescribed by Lyme physicians to manage Chronic Babesiosis. This trend           
 may follow the recent publication of several case reports demonstrating activity in immunosuppressed patients with acute babesiosis,           
 and animal data showing eradication of Babesia parasites, Tafenoquine (primarily as Arakoda).4 The Company believes                            
 the recent increases in sales of Arakoda have been driven by organic growth of these activities. There are no formal epidemiological           
 publications articulating the incidence or prevalence of Chronic Babesiosis, so these metrics must be inferred based on data for PTLDS         
 and the rate of coinfection with Babesia parasites. Thus, the cumulative case load of Chronic Babesiosis may be as high as1.01                 
 million patients in the United States.5 We believe, based on our market research that at least 37%